Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

380.78USD
8 Dec 2017
Change (% chg)

$7.17 (+1.92%)
Prev Close
$373.61
Open
$375.52
Day's High
$384.07
Day's Low
$373.00
Volume
663,918
Avg. Vol
834,272
52-wk High
$543.55
52-wk Low
$340.09

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $50,356.19
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

3:24pm GMT

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

3:23pm GMT

UPDATE 4-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)

3:20pm GMT

BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma

* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

6:04am GMT

BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD

* REGENERON ANNOUNCES FDA ACCEPTANCE OF SBLA FILING FOR 12-WEEK DOSING OF EYLEA® (AFLIBERCEPT) INJECTION FOR PATIENTS WITH WET AMD

11 Dec 2017

BRIEF-Regeneron And Decibel Therapeutics Announce Strategic Collaboration

* REGENERON AND DECIBEL THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP THERAPEUTICS FOR HEARING LOSS AND TINNITUS

29 Nov 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

27 Nov 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

27 Nov 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Nov 27 Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

27 Nov 2017

FTSE outperforms steady open for European shares; EDF slumps

MILAN, Nov 13 European shares steadied in early deals on Monday after losses last week but Britain's top FTSE 100 index rose as the pound weakened on British press reports of a building mutiny against Prime Minister Theresa May.

13 Nov 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.85 +0.30
Pfizer Inc. (PFE.N) $36.69 +0.12
Bayer AG (BAYGn.DE) €106.40 -0.25
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.66 -0.37
Merck & Co., Inc. (MRK.N) $56.68 -0.39
Amgen, Inc. (AMGN.OQ) $177.38 +1.12
Roche Holding Ltd. (ROG.S) CHF241.60 -0.10
Roche Holding Ltd. (RO.S) CHF243.90 -0.10
Eli Lilly and Co (LLY.N) $87.98 +1.27

Earnings vs. Estimates